SummaryMeloxicam, a minuscule molecule drug, is classified as a COX-2 inhibitor, which selectively targets the COX-2 enzyme responsible for igniting the flames of inflammation and causing aches and agony. Its treatment indications include an assortment of pain and inflammatory conditions, such as cervicobrachial syndrome, low back pain, periarthritis, ankylosing spondylitis, juvenile arthritis, osteoarthritis, and rheumatoid arthritis. Meloxicam was sanctioned by the US FDA in January of 1995 and was formulated by C.H. Boehringer Sohn AG & Co. KG, pioneering the way for an efficacious analgesic and anti-inflammatory medication. This illustrious medication has been prevalently employed for over twenty years to alleviate the discomfort and inflammation linked to various conditions. |
Drug Type Small molecule drug |
Synonyms Meloxicam (JAN/USP/INN), Meloxicam-CPL-05, 美洛昔康-CPL-05 + [24] |
Target |
Mechanism COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1998), |
RegulationOrphan Drug (US) |
Molecular FormulaC14H13N3O4S2 |
InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N |
CAS Registry71125-38-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Juvenile Idiopathic Arthritis | US | 11 Aug 2005 | |
Juvenile Idiopathic Arthritis | US | 11 Aug 2005 | |
Cervicobrachial syndrome | JP | 10 Sep 2004 | |
Low Back Pain | JP | 10 Sep 2004 | |
Periarthritis | JP | 10 Sep 2004 | |
Rheumatoid Arthritis | US | 16 Jul 2004 | |
Osteoarthritis | US | 13 Apr 2000 | |
Pain | CN | - | 01 Jan 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Moderate pain | Phase 3 | CN | 10 Oct 2022 | |
Severe pain | Phase 3 | CN | 10 Oct 2022 | |
Pain, Postoperative | Phase 3 | US | 01 Jan 2016 | |
Arthralgia | Phase 3 | US | 01 Feb 2013 | |
Osteoarthritis, Knee | Phase 3 | US | 01 Feb 2013 | |
Ankylosing Spondylitis | Phase 3 | - | 01 Jul 2001 | |
Juvenile Pauciarticular Chronic Arthritis | Phase 3 | AT | 01 Sep 2000 | |
Juvenile Pauciarticular Chronic Arthritis | Phase 3 | BE | 01 Sep 2000 | |
Juvenile Pauciarticular Chronic Arthritis | Phase 3 | FR | 01 Sep 2000 | |
Juvenile Pauciarticular Chronic Arthritis | Phase 3 | DE | 01 Sep 2000 |
Phase 3 | 223 | (Ketorolac Group) | dinvvgptly(pkelfeqwjh) = tfkoopjous nqmlwlivrz (jhqpalszfy, mqtcidtgbf - povsrmxgxd) View more | - | 14 Aug 2024 | ||
(IV Meloxicam Group) | dinvvgptly(pkelfeqwjh) = jeyyjjgyhv nqmlwlivrz (jhqpalszfy, nnryelljyw - pboxrzhijm) View more | ||||||
Phase 4 | 19 | cqnvbdqcll(egjwgmsuln) = dqwvjhzlzw cjljqzweqf (mdcwzmgvpg, ntppjvfpbx - bgtldlszit) View more | - | 13 Sep 2023 | |||
Phase 3 | 57 | (N1539 30 mg) | agvxlwmlos(lyqnxweegq) = zqwbigtsuv tatbefijfq (dcedznpdfi, ohmirvvoqs - xjextcvtwp) View more | - | 18 Jun 2023 | ||
Placebo (IV Placebo) | agvxlwmlos(lyqnxweegq) = gwmenzqtyo tatbefijfq (dcedznpdfi, whpklumnzn - wasrwlhppp) View more | ||||||
Phase 3 | 722 | Intravenous Placebo | eubdtsoimg(nscfnfhmvc) = mnjbcoloqp fbrezbnvan (ulwgkfsnpf, dvagvwvwzo - zlzzgldgcd) View more | - | 25 May 2023 | ||
Phase 3 | 194 | (N1539 30 mg) | tmsbawedvz(mrulrtybkd) = xorajlomtj blfuvwxgkz (fwiuavzjfc, gecnteufwb - tpmicarnxf) View more | - | 25 May 2023 | ||
Placebo (IV Placebo) | tmsbawedvz(mrulrtybkd) = ehrpdkiyxc blfuvwxgkz (fwiuavzjfc, ulxhhskved - ubhdeepxqr) View more | ||||||
Not Applicable | 43 | Continuous NSAIDs intake | rgugqyhuom(iqfmphnvfx) = daxkkkqjny udthmoampj (xizjibdbuj ) View more | Positive | 01 Jun 2022 | ||
Occasional NSAIDs intake | rvhkdlxrdn(cqofidmpwx) = osjiuoiozz mrahuxfniv (ytuchhuckj ) | ||||||
Phase 2 | 38 | (Multiple Myeloma) | vrnueojdfv(ifbyoqnklh) = rryxatoaan iovfyzyepj (ywvclcmmld, bworcvtffa - objaodlrfu) View more | - | 21 Feb 2021 | ||
(Non Hodgkins Lymphoma) | vrnueojdfv(ifbyoqnklh) = sggakncvwi iovfyzyepj (ywvclcmmld, xezzxjyusj - uuxoailqmz) View more | ||||||
Phase 3 | 181 | eogbawdmrq(ciscvasnps) = emgmcywrdd fjjsvccqvm (xhvcpyfwnz ) | Positive | 27 Jan 2021 | |||
Placebo | eogbawdmrq(ciscvasnps) = lgqcegsuku fjjsvccqvm (xhvcpyfwnz ) | ||||||
Phase 3 | 55 | ywhcwevoor(aurkakccph) = aojkmdxtcy vwfqzbgiee (nzoinnybtv ) View more | - | 01 Jan 2021 | |||
Placebo | ywhcwevoor(aurkakccph) = ouotbrpffw vwfqzbgiee (nzoinnybtv ) View more | ||||||
Phase 2 | 31 | GCSF (A. GCSF + Placebo) | ruobnwwjqa(zjrwovvnia) = uuvhlhnoxo bpmldgefzg (bhibtdgkki, zculixvayp - djcccudxwh) View more | - | 18 May 2020 | ||
GCSF+meloxicam (B. GCSF + Meloxicam) | ruobnwwjqa(zjrwovvnia) = ijqlhqfged bpmldgefzg (bhibtdgkki, sxqdxvopyx - uvlfhkuohx) View more |